Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.

Clinical trial NCT05841771 · RECRUITING

Trial details

NCT number: NCT05841771
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hypomethylating Agent Venetoclax Myeloid Malignancy

Start date: 2023-01-01
Primary completion: 2024-12-31
Enrollment: 78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.